Euglycemic Diabetic Ketoacidosis in a Diabetic Patient Treated with SGLT2 Inhibitor

Authors:
  • LOLavrynenko Olga
    Lavrynenko Olga
  • SHSantos Hector
    Santos Hector
  • GAGarza Amando
    Garza Amando
  • QRQazi Rayan
    Qazi Rayan
  • CLCobos Leopoldo
    Cobos Leopoldo

Abstract
Diabetic ketoacidosis (DKA) is a life - threatening complication and must be diagnosed and treated promptly and aggressively. The classic triad of DKA is: Hyperglycemia (blood glucose (BG) > 250 mg/dl: Anion gap metabolic acidosis (pH < 7.30 and bicarbonate < 18 mEq/L): And ketonemia. With Food and Drug Administration (FDA) approval of the sodium - glucose transporter 2 inhibitors (SGLT2i), DKA can occur with BG levels below 200 mg/dl and has been defined as euglycemic DKA (EuDKA). Due to the absence of hyperglycemia, the diagnosis of EuDKA is challenging and often delayed.